Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy

These findings provide a quantitative basis for evaluating the risk of major bleeding in individual patients at the start of outpatient therapy with warfarin and identify predictive factors known at the beginning of therapy.

Abstract

These findings provide a quantitative basis for evaluating the risk of major bleeding in individual patients at the start of outpatient therapy with warfarin. Whether the risk of bleeding can be reduced in high-risk patients without reducing the benefit of therapy remains to be determined.